Generex Biotechnology Corporation
GNBTQ
OTC PK
| 04/30/2021 | 01/31/2021 | 10/31/2020 | 07/31/2020 | 04/30/2020 | |
|---|---|---|---|---|---|
| Revenue | 692.70K | 1.17M | 2.03M | 2.66M | 2.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 692.70K | 1.17M | 2.03M | 2.66M | 2.03M |
| Cost of Revenue | 358.60K | 408.90K | 469.60K | 579.90K | 406.80K |
| Gross Profit | 334.10K | 761.80K | 1.56M | 2.08M | 1.62M |
| SG&A Expenses | 29.88M | 28.39M | 26.12M | 17.91M | 23.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.00M | 32.69M | 29.53M | 20.60M | 25.02M |
| Operating Income | -34.31M | -31.52M | -27.50M | -17.94M | -23.00M |
| Income Before Tax | -38.79M | -53.04M | -35.91M | -34.23M | -27.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.79 | -53.04 | -35.91 | -34.23 | -27.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.53M | 924.40K | 968.90K | 897.10K | 1.16M |
| Net Income | -37.26M | -52.11M | -34.94M | -33.34M | -26.45M |
| EBIT | -34.31M | -31.52M | -27.50M | -17.94M | -23.00M |
| EBITDA | -33.30M | -30.57M | -26.61M | -17.11M | -22.28M |
| EPS Basic | -0.39 | -0.55 | -0.43 | -0.45 | -0.41 |
| Normalized Basic EPS | -0.21 | -0.30 | -0.23 | -0.24 | -0.33 |
| EPS Diluted | -0.52 | -0.55 | -0.44 | -0.46 | -0.42 |
| Normalized Diluted EPS | -0.22 | -0.30 | -0.23 | -0.24 | -0.33 |
| Average Basic Shares Outstanding | 401.93M | 364.30M | 319.78M | 292.73M | 259.86M |
| Average Diluted Shares Outstanding | 427.73M | 364.30M | 319.78M | 292.73M | 259.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
